Research graph
References from Gleason pattern 4 length and active surveillance eligibility in Grade Group 2–4 prostate cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
Time trends and variation in the use of active surveillance for management of low‐risk prostate cancer in the US
10.1001/jamanetworkopen.2023.1439 · 2023 · External reference
Long‐term follow‐up of a large active surveillance cohort of patients with prostate cancer
10.1200/jco.2014.55.1192 · 2015 · External reference
Fifteen‐year outcomes after monitoring, surgery, or radiotherapy for prostate cancer
10.1056/nejmoa2214122 · 2023 · External reference
Rethinking Gleason pattern quantification in predicting metastasis: results of 20 years of follow‐up in the Rotterdam section of the European randomized study of screening for prostate cancer
10.1111/his.70052 · 2026 · External reference
Disease‐specific death and metastasis do not occur in patients with Gleason score ≤6 at radical prostatectomy
10.1111/bju.12879 · 2015 · External reference
Risk of biochemical recurrence in patients with grade group 1 prostate cancer with extraprostatic extension treated with radical prostatectomy
10.1097/ju.0000000000003825 · 2024 · External reference
Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology
10.6004/jnccn.2023.0050 · 2023 · External reference
A new risk classification system for therapeutic decision making with intermediate‐risk prostate cancer patients undergoing dose‐escalated external‐beam radiation therapy
10.1016/j.eururo.2013.03.033 · 2013 · External reference
Clinically localized prostate cancer: AUA/ASTRO guideline, part I: introduction, risk assessment, staging, and risk‐based management. [Miscellaneous Article]
10.1097/ju.0000000000002757 · 2022 · External reference
EAU‐EANM‐ESTRO‐ESUR‐ISUP‐SIOG guidelines on prostate cancer—2024 update. Part I: screening, diagnosis, and local treatment with curative intent
10.1016/j.eururo.2024.03.027 · 2024 · External reference
The absolute volume of Gleason pattern 4 on radical prostatectomy is more strongly associated with advanced stage and biochemical recurrence than Gleason grade groups
10.1097/ju.0000000000004484 · 2025 · External reference
10.64898/2026.02.27.26347289
10.64898/2026.02.27.26347289 · External reference
Quantification of prostate cancer Gleason pattern 4 to predict oncological outcome
10.1111/bju.16884 · 2025 · External reference
Oncologic outcomes of total length Gleason pattern 4 on biopsy in men with grade group 2 prostate cancer
10.1097/ju.0000000000002685 · 2022 · External reference
Unresolved reference
2021 · External reference
Welcome to the tidyverse
10.21105/joss.01686 · 2019 · External reference
Reproducible summary tables with the gtsummary package
10.32614/rj-2021-053 · 2021 · External reference
Clinical usefulness of total length of Gleason pattern 4 on biopsy in men with grade group 2 prostate cancer
10.1016/j.juro.2018.07.062 · 2019 · External reference
Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
10.1001/jama.280.11.969 · 1998 · External reference
The use and short‐term outcomes of active surveillance in men with National Comprehensive Cancer Network favorable intermediate‐risk prostate cancer: the initial Michigan urological surgery improvement collaborative experience
10.1097/ju.0000000000003012 · 2023 · External reference
Revisiting prostate cancer active surveillance candidacy
10.1016/s1470-2045(25)00438-3 · 2025 · External reference
Identifying men who can remain on active surveillance despite biopsy reclassification to grade group 2 prostate cancer
10.1097/ju.0000000000003461 · 2023 · External reference
Quantification of Gleason pattern 4 metrics identifies pathologic progression in patients with grade group 2 prostate cancer on active surveillance
10.1016/j.clgc.2024.102204 · 2024 · External reference
Cancer statistics, 2026
2026 · External reference
Unresolved reference
2026 · External reference
Prostate cancer grade migration and facility‐level treatment trends for grade group 1 disease
10.1093/jncics/pkad018 · 2023 · External reference
Differences in survival of prostate cancer Gleason 8–10 disease and the establishment of a new Gleason survival grading system
10.1002/cam4.3571 · 2020 · External reference
Cost‐effectiveness and evidence gaps surrounding PSMA‐PET for recurrent prostate cancer evaluation
10.1001/jamanetworkopen.2025.39250 · 2025 · External reference
Adverse effects of androgen deprivation therapy and strategies to mitigate them
10.1016/j.eururo.2014.07.010 · 2015 · External reference
Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings
10.1097/pas.0b013e3182217b79 · 2011 · External reference
Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue
10.1111/j.1365-2559.2008.03087.x · 2008 · External reference
Evaluating tumor quantification in place of proportions in prostate cancer: principles of the ProQuant group
10.1016/j.eururo.2025.11.013 · 2026 · External reference
Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stage
10.1111/his.15231 · 2024 · External reference
Long‐term outcomes of cribriform‐positive and cribriform‐negative prostate cancer treated with radical prostatectomy in the ProtecT trial
10.1111/bju.70261 · 2026 · External reference
